Amgen study shows Repatha does not adversely affect cognitive function

Amgen has announced new clinical trial data showing that its cholesterol therapy Repatha does not have a negative impact on patients' cognitive performance.

Detailed results from the cognitive function study EBBINGHAUS showed that the 1,974 patients enrolled in the Repatha cardiovascular outcomes study FOURIER did not experience an impact on their cognitive function.

The effect of Repatha was shown to be non-inferior to placebo, with no statistical difference between Repatha and placebo on key cognitive domains such as working memory, memory function and psychomotor speed.

This was true even for patients who reached a low-density lipoprotein (LDL) cholesterol level below 25 mg/dL, and puts to rest concerns that lower LDL cholesterol levels could lead to negative effects on memory or other cognitive functions.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "These results further support the safety of Repatha as an effective LDL-lowering therapy with no observed negative effects on memory or other cognitive functions."

A previous study showed that Repatha may also be associated with a reduced need for apheresis in patients with high cholesterol.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.